WEKO3
アイテム
{"_buckets": {"deposit": "5e2e3e86-8011-42de-87f1-d24367111705"}, "_deposit": {"created_by": 2, "id": "16797", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "16797"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00016797", "sets": ["1304"]}, "author_link": ["64981", "64989", "64990", "64984", "64982", "64988", "64986", "64983", "64985", "64987"], "item_3_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2009-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "38", "bibliographicPageStart": "33", "bibliographicVolumeNumber": "54", "bibliographic_titles": [{"bibliographic_title": "Acta medica Nagasakiensia"}]}]}, "item_3_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Insulin is a major autoantigen responsible for the pathogenesis of type 1 diabetes, and its B-chain peptide B:9-23 has been suggested to contain critically important epitopes in the NOD mouse. We have previously demonstrated that the altered peptide ligand of B:9-23 peptide with alanine substitutions at positions 16 and 19 (A16,19 APL) suppresses insulitis and reduces the incidence of diabetes when administered intranasally together with cholera toxin (CT). In this study, we extended the previous findings to determine whether mucosal administration of the A16,19APL without the use of toxic CT is efficacious for diabetes prevention. To this end,we linked the A16,19APL to the C-terminus of non-toxic cholera toxin (CTB) B subunit and the chimeric fusion protein was produced in methyloprophic yeast Pichia pastoris. Although intranasal administration of the recombinant CTB-A16,19APL fusion protein extracted fromthe yeast cells failed to prevent the progression to diabetes, oral administration of the live yeast cells producing the chimeric protein resulted in more than 50% reduction of the development of diabetes, albeit the fact that protective efficacy did not reach the significance level by life table analysis (P= 0.08). Furthermore, the expression of insulin autoantibodies was not altered throughout the course of oral immunization experiment. These results demonstrated that the efficacy of recombinant CTB-A16,19APL for oral immunization has much room for improvement. Nevertheless, oral administration of recombinant yeast or other edible materials such as food plants engineered to produce altered autoantigenic peptide could potentially become a novel non-invasive immunotherapeutic strategy for type 1 diabetes. (250 word)", "subitem_description_type": "Abstract"}]}, "item_3_description_64": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Acta medica Nagasakiensia, 54(2), pp.33-38 ; 2009", "subitem_description_type": "Other"}]}, "item_3_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagasaki University School of Medicine"}]}, "item_3_relation_42": {"attribute_name": "関係URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "http://joi.jlc.jst.go.jp/JST.JSTAGE/amn/54.33"}]}]}, "item_3_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00508435", "subitem_source_identifier_type": "NCID"}]}, "item_3_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00016055", "subitem_source_identifier_type": "ISSN"}]}, "item_3_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Zhou, Hongbo"}], "nameIdentifiers": [{"nameIdentifier": "64981", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Abiru, Norio"}], "nameIdentifiers": [{"nameIdentifier": "64982", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Arakawa, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "64983", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sakima, Rina"}], "nameIdentifiers": [{"nameIdentifier": "64984", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyata, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "64985", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kobayashi, Masakazu"}], "nameIdentifiers": [{"nameIdentifier": "64986", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukushima, Keiko"}], "nameIdentifiers": [{"nameIdentifier": "64987", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawasaki, Eiji"}], "nameIdentifiers": [{"nameIdentifier": "64988", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamasaki, Hironori"}], "nameIdentifiers": [{"nameIdentifier": "64989", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Eguchi, Katsumi"}], "nameIdentifiers": [{"nameIdentifier": "64990", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-23"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "acta_54_2_33.pdf", "filesize": [{"value": "305.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 305700.0, "url": {"label": "acta_54_2_33.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/16797/files/acta_54_2_33.pdf"}, "version_id": "0bc8b8be-2d4c-4971-b852-495821f04800"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Type 1 diabetes", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Insulin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Oral tolerance", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Yeast", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Altered peptide ligand", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Cholera toxin B subunit", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Oral Administration of Recombinant Live Yeast Producing Altered Peptide Ligand Derived from Insulin B:9-23 Peptide Linked to Cholera Toxin B Subunit Suppresses Development of Autoimmune Diabetes in NOD Mice", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Oral Administration of Recombinant Live Yeast Producing Altered Peptide Ligand Derived from Insulin B:9-23 Peptide Linked to Cholera Toxin B Subunit Suppresses Development of Autoimmune Diabetes in NOD Mice"}]}, "item_type_id": "3", "owner": "2", "path": ["1304"], "permalink_uri": "http://hdl.handle.net/10069/22686", "pubdate": {"attribute_name": "公開日", "attribute_value": "2010-01-06"}, "publish_date": "2010-01-06", "publish_status": "0", "recid": "16797", "relation": {}, "relation_version_is_last": true, "title": ["Oral Administration of Recombinant Live Yeast Producing Altered Peptide Ligand Derived from Insulin B:9-23 Peptide Linked to Cholera Toxin B Subunit Suppresses Development of Autoimmune Diabetes in NOD Mice"], "weko_shared_id": -1}
Oral Administration of Recombinant Live Yeast Producing Altered Peptide Ligand Derived from Insulin B:9-23 Peptide Linked to Cholera Toxin B Subunit Suppresses Development of Autoimmune Diabetes in NOD Mice
http://hdl.handle.net/10069/22686
http://hdl.handle.net/10069/22686ff18e3c9-f5bb-4366-98aa-3b4f96bfedae
名前 / ファイル | ライセンス | アクション |
---|---|---|
acta_54_2_33.pdf (305.7 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2010-01-06 | |||||
タイトル | ||||||
タイトル | Oral Administration of Recombinant Live Yeast Producing Altered Peptide Ligand Derived from Insulin B:9-23 Peptide Linked to Cholera Toxin B Subunit Suppresses Development of Autoimmune Diabetes in NOD Mice | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Type 1 diabetes | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Insulin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Oral tolerance | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Yeast | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Altered peptide ligand | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Cholera toxin B subunit | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
著者 |
Zhou, Hongbo
× Zhou, Hongbo× Abiru, Norio× Arakawa, Takeshi× Sakima, Rina× Miyata, Takeshi× Kobayashi, Masakazu× Fukushima, Keiko× Kawasaki, Eiji× Yamasaki, Hironori× Eguchi, Katsumi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Insulin is a major autoantigen responsible for the pathogenesis of type 1 diabetes, and its B-chain peptide B:9-23 has been suggested to contain critically important epitopes in the NOD mouse. We have previously demonstrated that the altered peptide ligand of B:9-23 peptide with alanine substitutions at positions 16 and 19 (A16,19 APL) suppresses insulitis and reduces the incidence of diabetes when administered intranasally together with cholera toxin (CT). In this study, we extended the previous findings to determine whether mucosal administration of the A16,19APL without the use of toxic CT is efficacious for diabetes prevention. To this end,we linked the A16,19APL to the C-terminus of non-toxic cholera toxin (CTB) B subunit and the chimeric fusion protein was produced in methyloprophic yeast Pichia pastoris. Although intranasal administration of the recombinant CTB-A16,19APL fusion protein extracted fromthe yeast cells failed to prevent the progression to diabetes, oral administration of the live yeast cells producing the chimeric protein resulted in more than 50% reduction of the development of diabetes, albeit the fact that protective efficacy did not reach the significance level by life table analysis (P= 0.08). Furthermore, the expression of insulin autoantibodies was not altered throughout the course of oral immunization experiment. These results demonstrated that the efficacy of recombinant CTB-A16,19APL for oral immunization has much room for improvement. Nevertheless, oral administration of recombinant yeast or other edible materials such as food plants engineered to produce altered autoantigenic peptide could potentially become a novel non-invasive immunotherapeutic strategy for type 1 diabetes. (250 word) | |||||
書誌情報 |
Acta medica Nagasakiensia 巻 54, 号 2, p. 33-38, 発行日 2009-12 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00016055 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00508435 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
出版者 | ||||||
出版者 | Nagasaki University School of Medicine | |||||
関係URI | ||||||
関連名称 | http://joi.jlc.jst.go.jp/JST.JSTAGE/amn/54.33 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Acta medica Nagasakiensia, 54(2), pp.33-38 ; 2009 |